Collectively, these studies show that CDKi’s induce senescence in breast cancer cells and suggest that BET inhibitors have excellent potential to be used as senostatics or senolytics to delay relapse and/or overcome palbociclib resistance. The gene discussed is DNER; the disease is breast carcinoma.